AbbVie Faces FDA Rejection On Manufacturing Issues For Wrinkle Drug

AbbVie Faces FDA Rejection On Manufacturing Issues For Wrinkle Drug

Summary

AbbVie Inc. shares are down during Friday’s premarket session following a Complete Response Letter (CRL) from the FDA regarding the Biologics License Applicat...

Description

AbbVie Inc. shares are down during Friday’s premarket session following a Complete Response Letter (CRL) from the FDA regarding the Biologics License Applicat...

Original reporting

AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.

Open original source

Related coverage